Please use this identifier to cite or link to this item: http://hdl.handle.net/2067/51564
DC FieldValueLanguage
dc.contributor.authorGevi, Federicait
dc.contributor.authorFanelli, Giuseppinait
dc.contributor.authorZolla, Lelloit
dc.date.accessioned2024-07-23T07:49:36Z-
dc.date.available2024-07-23T07:49:36Z-
dc.date.issued2018it
dc.identifier.issn2041-4889it
dc.identifier.urihttp://hdl.handle.net/2067/51564-
dc.description.abstractMale hypogonadism associated with insulin resistance (IR) very often leads to metabolic syndrome, at variance with hypogonadism in its first stadium of insulin sensitivity (IS). A plasma metabolomic investigation of these patients can provide useful information in comparison with the values of IS patients. To this aim plasma from insulin-resistant males with hypogonadism were analysed by using ultra high-performance liquid chromatography (UHPLC) and high-resolution mass spectrometry (HRMS). Thus, metabolites were compared to the controls through multivariate statistical analysis and grouped by metabolic pathways. Metabolite database searches and pathway analyses identified imbalances in 18-20 metabolic pathways. Glucose metabolism (e.g., glycolysis and the Krebs cycle) is fuelled by amino acids degradation, in particular of branched amino acids, in individuals with lean body mass. Gluconeogenesis is strongly activated. Some crucial pathways such as glycerol are skewed. Mitochondrial electron transport is affected with a reduction in ATP production. Beta-oxidation of short and medium chain fatty acids did not represent an energy source in hypogonadism, at variance with long and branched fatty acids, justifying the increase in fat mass. Carnosine and β-alanine are strongly reduced resulting in increased fatigue and mental confusion. A comparison of IR with IS male hypogonadism will contribute to a better understanding of how these two hormones work in synergy or antagonise each other in humans. It could also help to select patients who will respond to hormone treatment, and provide accurate biomarkers to measure the response to treatment eventually leading to better strategies in preventing systemic complications in patients not fit for hormone replacement therapy.it
dc.format.mediumELETTRONICOit
dc.language.isoengit
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleMetabolic patterns in insulin-resistant male hypogonadismit
dc.typearticle*
dc.identifier.doi10.1038/s41419-018-0587-9it
dc.identifier.pmid29867095it
dc.identifier.scopus2-s2.0-85047862536it
dc.relation.journalCELL DEATH & DISEASEit
dc.relation.firstpage1it
dc.relation.lastpage11it
dc.relation.numberofpages11it
dc.relation.article671it
dc.relation.volume9it
dc.relation.issue6it
dc.description.numberofauthors3it
dc.type.refereeREF_1it
dc.type.miur262*
item.fulltextWith Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
item.grantfulltextrestricted-
item.openairetypearticle-
item.cerifentitytypePublications-
crisitem.journal.journalissn2041-4889-
crisitem.journal.anceE201263-
Appears in Collections:A1. Articolo in rivista
Files in This Item:
File Description SizeFormat Existing users please
41419_2018_Article_587.pdf2.38 MBAdobe PDF    Request a copy
Show simple item record

SCOPUSTM   
Citations

24
Last Week
0
Last month
checked on Sep 8, 2024

Page view(s)

48
checked on Sep 11, 2024

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons